pgrn recombinant protein Search Results


progranulin levels  (Boster Bio)
94
Boster Bio progranulin levels
A – Comparison of serum <t>progranulin</t> levels between the antral ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4237.35 ±1091.30 vs. 3052.66 ±626.88) – post-treatment (3607.7 ±869.4 vs. 3052.66 ±626.88), B – comparison of serum progranulin between the duodenal ulcer group and the control group, before treatment and after treatment. Respectively, mean values; re-treatment (4682.64 ±1501.46 vs. 3055.66 ±626.88) – post-treatment (4286.5 ±1208.78 vs. 3052.66 ±626.88), C – comparison of serum progranulin levels between the ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4460 ±1315 vs. 3052.66 ±626.88) – post-treatment (3947.1 ±1094.64 vs. 3052.66 ±626.88)
Progranulin Levels, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pgrn+recombinant+protein/PGRN+Progranulin+Human+Recombinant+Protein/pmc06300845-61-4-18
Average 94 stars, based on 1 article reviews
progranulin levels - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
recombinant human progranulin protein, cf  (Bio-Techne corporation)
94
Bio-Techne corporation recombinant human progranulin protein, cf
A – Comparison of serum <t>progranulin</t> levels between the antral ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4237.35 ±1091.30 vs. 3052.66 ±626.88) – post-treatment (3607.7 ±869.4 vs. 3052.66 ±626.88), B – comparison of serum progranulin between the duodenal ulcer group and the control group, before treatment and after treatment. Respectively, mean values; re-treatment (4682.64 ±1501.46 vs. 3055.66 ±626.88) – post-treatment (4286.5 ±1208.78 vs. 3052.66 ±626.88), C – comparison of serum progranulin levels between the ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4460 ±1315 vs. 3052.66 ±626.88) – post-treatment (3947.1 ±1094.64 vs. 3052.66 ±626.88)
Recombinant Human Progranulin Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pgrn+recombinant+protein/Recombinant+Human+Progranulin+Protein%2C+CF/bio-techne+corporation___2420-pg
Average 94 stars, based on 1 article reviews
recombinant human progranulin protein, cf - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
recombinant rat progranulin/pgrn flag protein  (Novus Biologicals)
N/A
Recombinant Rat Progranulin/PGRN FLAG Protein
   Buy from Supplier
recombinant rat progranulin/pgrn protein  (Novus Biologicals)
N/A
Recombinant Rat Progranulin/PGRN Protein
   Buy from Supplier
recombinant human granulin/pgrn protein  (Elabscience Biotechnology)
N/A
Granulins are a family of secreted, glycosylated peptides that are cleaved from a single precursor protein with 7.5 repeats of a highly conserved 12-cysteine granulin/epithelin motif. The precursor protein, progranulin, is also called proepithelin and
   Buy from Supplier

Image Search Results


A – Comparison of serum progranulin levels between the antral ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4237.35 ±1091.30 vs. 3052.66 ±626.88) – post-treatment (3607.7 ±869.4 vs. 3052.66 ±626.88), B – comparison of serum progranulin between the duodenal ulcer group and the control group, before treatment and after treatment. Respectively, mean values; re-treatment (4682.64 ±1501.46 vs. 3055.66 ±626.88) – post-treatment (4286.5 ±1208.78 vs. 3052.66 ±626.88), C – comparison of serum progranulin levels between the ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4460 ±1315 vs. 3052.66 ±626.88) – post-treatment (3947.1 ±1094.64 vs. 3052.66 ±626.88)

Journal: Przegla̜d Gastroenterologiczny

Article Title: Can serum progranulin levels be a biomarker following gastric ulcer therapy?

doi: 10.5114/pg.2018.79812

Figure Lengend Snippet: A – Comparison of serum progranulin levels between the antral ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4237.35 ±1091.30 vs. 3052.66 ±626.88) – post-treatment (3607.7 ±869.4 vs. 3052.66 ±626.88), B – comparison of serum progranulin between the duodenal ulcer group and the control group, before treatment and after treatment. Respectively, mean values; re-treatment (4682.64 ±1501.46 vs. 3055.66 ±626.88) – post-treatment (4286.5 ±1208.78 vs. 3052.66 ±626.88), C – comparison of serum progranulin levels between the ulcer group and the control group, before treatment and after treatment. Respectively, mean values; pre-treatment (4460 ±1315 vs. 3052.66 ±626.88) – post-treatment (3947.1 ±1094.64 vs. 3052.66 ±626.88)

Article Snippet: Serum VEGF, TNF-α, and progranulin levels were studied with enzyme-linked immunosorbent assay (ELISA) with a commercial ELISA kit (Boster Immunoleader, USA).

Techniques: Comparison, Control

Comparison of serum progranulin, VEGF, and TNF-α levels between the antral ulcer group and the duodenal ulcer group, pre-treatment and post-treatment

Journal: Przegla̜d Gastroenterologiczny

Article Title: Can serum progranulin levels be a biomarker following gastric ulcer therapy?

doi: 10.5114/pg.2018.79812

Figure Lengend Snippet: Comparison of serum progranulin, VEGF, and TNF-α levels between the antral ulcer group and the duodenal ulcer group, pre-treatment and post-treatment

Article Snippet: Serum VEGF, TNF-α, and progranulin levels were studied with enzyme-linked immunosorbent assay (ELISA) with a commercial ELISA kit (Boster Immunoleader, USA).

Techniques: Comparison

A – Comparison of between pre-treatment and post-treatment serum progranulin levels for the ulcer group. Respectively, mean values; pre-treatment (4460.00 ±1315.04) vs. post-treatment (3947.1 ±1094.65), B – comparison of between pre-treatment and post-treatment VEGF levels for the ulcer group. Respectively, mean values; pre-treatment (103.55 ±101.06) vs. post-treatment (77.38.1 ±67.64), C – comparison of between pre-treatment and post-treatment TNF-α levels for the ulcer group. Respectively, mean values; pre-treatment (341.66 ±426.10) vs. post-treatment (297.14 ±424.64)

Journal: Przegla̜d Gastroenterologiczny

Article Title: Can serum progranulin levels be a biomarker following gastric ulcer therapy?

doi: 10.5114/pg.2018.79812

Figure Lengend Snippet: A – Comparison of between pre-treatment and post-treatment serum progranulin levels for the ulcer group. Respectively, mean values; pre-treatment (4460.00 ±1315.04) vs. post-treatment (3947.1 ±1094.65), B – comparison of between pre-treatment and post-treatment VEGF levels for the ulcer group. Respectively, mean values; pre-treatment (103.55 ±101.06) vs. post-treatment (77.38.1 ±67.64), C – comparison of between pre-treatment and post-treatment TNF-α levels for the ulcer group. Respectively, mean values; pre-treatment (341.66 ±426.10) vs. post-treatment (297.14 ±424.64)

Article Snippet: Serum VEGF, TNF-α, and progranulin levels were studied with enzyme-linked immunosorbent assay (ELISA) with a commercial ELISA kit (Boster Immunoleader, USA).

Techniques: Comparison